

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 6-K  
June 07, 2011

---

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

For the month of June, 2011

Commission File Number 0-16174

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190**

**Petach Tikva 49131 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F     X     Form  
40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):     

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Website: [www.tevapharm.com](http://www.tevapharm.com)

**Reinspection Date Scheduled for Jerusalem Facility**

As an anticipated follow-up to the warning letter Teva received on January 31, 2011 and the subsequent corrective actions Teva implemented, the Food and Drug Administration Office of Compliance is scheduled to begin its re-inspection of Teva's Jerusalem facility on June 13, 2011.

-2-

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TEVA  
PHARMACEUTICAL  
INDUSTRIES  
LIMITED  
(Registrant)

By:     /s/ Eyal  
    Desheh  
    —  
    Name: Eyal  
    Desheh  
    Title: Chief  
    Financial  
    Officer

Date: June 7, 2011

-3-